Company intelligence / Profile preview

PERYA

Roscoff, Bretagne, Francego-perya.com ↗

Ownership: Private
Employees: ~10
Development stage: Commercial

Overview

Perha Pharmaceuticals is developing low molecular weight kinase inhibitors derived from marine natural products. Their lead programs target cognitive deficits associated with Down syndrome and Alzheimer's disease, as well as ototoxic hearing loss. The company has filed patents on purine derivatives for neurodegenerative and neuro-inflammatory disorders. No clinical results have been published yet; the pipeline appears to be at the preclinical or early translational stage[1][2][3][4].

Therapeutic areas: ImmunologyNeurology
Modalities: Small molecule
Industry: Biotech

Partnerships

No major pharmaceutical or biotech partnerships disclosed.

Beyond the preview

Go deeper on PERYA.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PERYA.

Explore the full profile